Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Among authors: verslype c. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients.
Saalfeld S, Kreher R, Hille G, Niemann U, Hinnerichs M, Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Berg T, Klümpen HJ, Benckert J, Gasbarrini A, Amthauer H, Sangro B, Malfertheiner P, Preim B, Ricke J, Seidensticker M, Pech M, Surov A. Saalfeld S, et al. Among authors: verslype c. J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):2301-2309. doi: 10.1002/jcsm.13315. Epub 2023 Aug 17. J Cachexia Sarcopenia Muscle. 2023. PMID: 37592827 Free PMC article.
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022.
Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet JM, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O'Connor JM, O'Reilly EM, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E. Ducreux M, et al. Among authors: verslype c. ESMO Open. 2023 Jun;8(3):101567. doi: 10.1016/j.esmoop.2023.101567. Epub 2023 May 31. ESMO Open. 2023. PMID: 37263081 Free PMC article. Review.
Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma.
Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt KH, Benckert J. Leineweber CG, et al. Among authors: verslype c. Front Pharmacol. 2024 Jan 11;14:1354581. doi: 10.3389/fphar.2023.1354581. eCollection 2023. Front Pharmacol. 2024. PMID: 38273836 Free PMC article.
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma.
Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt KH, Benckert J. Leineweber CG, et al. Among authors: verslype c. Front Pharmacol. 2023 Mar 3;14:1124214. doi: 10.3389/fphar.2023.1124214. eCollection 2023. Front Pharmacol. 2023. PMID: 36937889 Free PMC article.
Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial.
Adam R, Badrudin D, Chiche L, Bucur P, Scatton O, Granger V, Ducreux M, Cillo U, Cauchy F, Lesurtel M, Mabrut JY, Verslype C, Coubeau L, Hardwigsen J, Boleslawski E, Muscari F, Jeddou H, Pezet D, Heyd B, Lucidi V, Geboes K, Lerut J, Majno P, Grimaldi L, Boukhedouni N, Piedvache C, Gelli M, Levi F, Lewin M. Adam R, et al. Among authors: verslype c. EClinicalMedicine. 2024 Apr 27;72:102608. doi: 10.1016/j.eclinm.2024.102608. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38721015 Free PMC article.
Aldehyde Dehydrogenase 2 (ALDH2): A novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay.
Ferreira IC, Torrejón E, Abecasis B, Alexandre BM, Gomes RA, Verslype C, van Pelt J, Barbas A, Simão D, Bandeiras TM, Bortoluzzi A, Rebelo SP. Ferreira IC, et al. Among authors: verslype c. SLAS Discov. 2024 Apr;29(3):100154. doi: 10.1016/j.slasd.2024.100154. Epub 2024 Mar 21. SLAS Discov. 2024. PMID: 38521503 Free article.
Correction: Méndez-Blanco et al. Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells. Cancers 2019, 11, 1984.
Méndez-Blanco C, Fondevila F, Fernández-Palanca P, García-Palomo A, van Pelt J, Verslype C, González-Gallego J, Mauriz JL. Méndez-Blanco C, et al. Among authors: verslype c. Cancers (Basel). 2023 Nov 30;15(23):5668. doi: 10.3390/cancers15235668. Cancers (Basel). 2023. PMID: 38067410 Free PMC article.
PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.
Cappuyns S, Philips G, Vandecaveye V, Boeckx B, Schepers R, Van Brussel T, Arijs I, Mechels A, Bassez A, Lodi F, Jaekers J, Topal H, Topal B, Bricard O, Qian J, Van Cutsem E, Verslype C, Lambrechts D, Dekervel J. Cappuyns S, et al. Among authors: verslype c. Nat Commun. 2023 Nov 29;14(1):7825. doi: 10.1038/s41467-023-43381-1. Nat Commun. 2023. PMID: 38030622 Free PMC article.
291 results